In today’s recent session, 2.78 million shares of the Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) have been traded, and its beta is 0.63. Most recently the company’s share price was $17.90, and it changed around $0.19 or 1.10% from the last close, which brings the market valuation of the company to $20.52B. TEVA at last check was trading at a discount to its 52-week high of $22.80, offering almost -27.37% off that amount. The share price’s 52-week low was $12.47, which indicates that the recent value has risen by an impressive 30.34% since then. We note from Teva- Pharmaceutical Industries Ltd. ADR’s average daily trading volume that its 10-day average is 10.13 million shares, with the 3-month average coming to 12.40 million.
Teva- Pharmaceutical Industries Ltd. ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.40. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended TEVA as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
Instantly TEVA has been showing a green trend so far today with a performance of 1.10% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 18.01 on recent trading dayincreased the stock’s daily price by 0.61%. The company’s shares are currently down -18.76% year-to-date, but still up 6.70% over the last five days. On the other hand, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) is 19.20% up in the 30-day period. We can see from the shorts that 38.7 million shares have been sold at a short interest cover period of 2.95 day(s).
The consensus price target as assigned by Wall Street analysts is $28, which translates to bulls needing to increase their stock price by 36.07% from its current value. Analyst projections state that TEVA is forecast to be at a low of $28 and a high of $28.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -9.62%. Teva- Pharmaceutical Industries Ltd. ADR earnings are expected to increase by 2.30% in 2025, but the outlook is positive 7.26% per year for the next five years.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR’s next quarterly earnings report is expected to be released on 2025-May-06. The average dividend yield for the past five years averaged 2.95 per year.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.00% of Teva- Pharmaceutical Industries Ltd. ADR shares, and 64.14% of them are in the hands of institutional investors. The stock currently has a share float of 64.14%. Teva- Pharmaceutical Industries Ltd. ADR stock is held by 754.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 3.7942% of the shares, which is about 42.99 million shares worth $698.55 million.
FMR LLC, with 3.7051% or 41.98 million shares worth $682.15 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Contrafund and iShares Trust-iShares Core MSCI EAFE ETF were the top two Mutual Funds as of Mar 31, 2025 . The former held 18.74 shares worth $335.08 million, making up 1.63% of all outstanding shares. On the other hand, iShares Trust-iShares Core MSCI EAFE ETF held roughly 7.16 shares worth around $128.07 million, which represents about 0.62% of the total shares outstanding.
